The United States Air Force, in partnership with the Coriell Personalized Medicine Collaborative, is undertaking Phase II of a study designed to evaluate the legitimacy of utilizing genetics and genomics in the clinical care setting: the Air Force Medical Service Personalized Medicine Clinical Utility Study.
Phase I of the CUS took place from 2011 to 2013 with 2,100 AFMS personnel with a focus on training and delivery of genetic risk information to patients. Phase II hopes to enroll an additional 4,500 participants over the next 18 months at various Air Force facilities nationwide, through participants providing informed consent and a small saliva sample.
Personal risk reports are provided to participants once they've completed a detailed online health questionnaire, which include details about many actionable health conditions such as type II diabetes, obesity, coronary artery disease and melanoma. Coriell's panel of board-certified genetic counselors are available to answer questions about risk reports at no charge to participants.
Enrollment is open to "active-duty members of the Air Force, retirees of the Air Force, or spouses of current active-duty members or retirees of the Air Force."
Please see the original post below from the U.S. Air Force for more on this opportunity.